Search Results
Aug 28, 2026, 12:23 ET LifeTech Scientific Corporation Announces 2026 Interim Results
interventional medical devices solutions to treat Peripheral Vascular Diseases (PVD).The products offered by the Group in the PVD business mainly include vena cava filters, thoracic aortic aneurysm stent grafts, abdominal aortic aneurysm stent grafts, iliac artery bifurcation stent grafts, aortic stent graft
More news about: LifeTech Scientific Corporation
Aug 28, 2026, 07:15 ET La FDA aprueba Mounjaro (tirzepatida) de Lilly para reducir el riesgo cardiovascular en adultos con diabetes tipo 2
o pide a otra persona que te inyecte en la parte superior, atrás del brazo. No inyectes Mounjaro en un músculo (intramuscularmente) ni en una vena (intravenosamente). Usa Mounjaro 1 vez a la semana, a cualquier hora del día. No mezcles insulina y Mounjaro en una
More news about: Eli Lilly and Company
Aug 24, 2026, 21:15 ET ICP DAS-BMP Pamerkan Inovasi TPU Medis di Ajang Medical Manufacturing Asia 2026
lebih baik bagi tenaga medis saat menggunakan kateter invasif dengan guidewire, seperti selang nasogastrik (nasogastric tube) dan kateter vena sentral (central venous catheter).Selain dua inovasi tersebut, ICP DAS-BMP juga akan memamerkan portofolio TPU untuk berbagai aplikasi
More news about: ICP DAS Co., Ltd.
Jul 07, 2026, 11:24 ET Nucleus Research Releases 2026 FCC Technology Value Matrix
Leaders in the FCC market include BlackLine, CCH Tagetik, Lucanet, OneStream, Oracle Cloud EPM, Planful, Prophix, and Vena.MIAMI, July 7, 2026 /PRNewswire/ -- Financial close and consolidation technology is becoming
More news about: Nucleus Research
Jun 09, 2026, 01:07 ET El stent venoso GORE® VIABAHN® FORTEGRA recibe aprobación MDR
fisiológico en la vena cava inferior", afirmó el profesor Stephen Black, catedrático de Cirugía Venosa del Hospital Guy's and St Thomas' de Londres e investigador principal global.El stent venoso FORTEGRA se evaluó en un ensayo prospectivo, el primero de su tipo en incluir la vena cava inferior,
More news about: W. L. Gore & Associates GmbH
Jun 09, 2026, 01:07 ET THE GORE® VIABAHN® FORTEGRA VENOUS STENT RECEIVES MDR APPROVAL
today CE Mark approval for the GORE® VIABAHN® FORTEGRA Venous Stent, indicated for use in the treatment of symptomatic inferior vena cava (IVC) and iliofemoral venous outflow obstruction. Building on the recent U.S. FDA approval, this milestone reflects Gore's commitment to expanding
More news about: W. L. Gore & Associates GmbH
Jun 09, 2026, 01:07 ET DER VENENSTENT GORE® VIABAHN® FORTEGRA ERHÄLT DIE MDR-ZULASSUNG
gab heute die CE-Zulassung für den GORE®VIABAHN®FORTEGRA Venenstent bekannt, der für die Behandlung symptomatischer inferiorer Vena cava (IVC) und iliofemoraler venöser Abflussbehinderungen indiziert ist.Aufbauend auf der jüngsten FDA-Zulassung in den USA spiegelt dieser Meilenstein
More news about: W. L. Gore & Associates GmbH
May 29, 2026, 09:43 ET El sistema VitaSmart™ HOPE de Bridge to Life validado como tecnología superior para preservación de órganos
ensayo multicéntrico aleatorizado realizado en Estados Unidos para evaluar el impacto clínico de la perfusión oxigenada hipotérmica (HOPE) a través de la vena porta en el trasplante hepático con donantes de alto riesgo con criterios extendidos, incluyendo injertos de donantes con muerte cerebral (DBD) y donantes
More news about: Bridge to Life, Ltd.
May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
vein thrombosis, pulmonary embolism, pelvic venous thrombosis, cerebral venous sinus thrombosis, subclavian and axillary vein thrombosis, and inferior vena cava thrombosis. In clinical trials, deaths due to VTE have been reported in patients treated with Verzenio.Verzenio has not been studied in
More news about: Eli Lilly and Company
May 11, 2026, 08:00 ET ProLytics Consulting Group Named Technology Partner of the Year by Vena Solutions
co-development approach, and deep platform expertise within the Vena ecosystemTORONTO, May 11, 2026 /PRNewswire/ - Vena Solutions has named ProLytics Consulting Group Technology Partner of the Year.
More news about: ProLytics Consulting Group
May 05, 2026, 11:35 ET Disposable Ostomy Bags Market to Reach USD 3.9 Billion by 2032, Driven by Rising Colorectal Disease Burden and Advancements in Patient-Centric Care Solutions: Verified Market Research
Global Interventional Radiology Products Market Size By Type (Catheters, Stents, Inferior Vena Cava(IVC) Filters, Hemodynamic Flow Alteration Devices, Angioplasty Ballons, Thrombectomy Systems, Embolization Devices, Biopsy Needles, Accessories)
More news about: Verified Market Research
Mar 31, 2026, 12:40 ET LifeTech Scientific Corporation Announces 2025 Annual Results: Steady Revenue Growth with Adjusted Net Profit Increasing 24.9%
comprehensive interventional medical devices solutions to treat peripheral vascular diseases. Products offered by the Group in the PVD business mainly included vena cava filters, thoracic aortic aneurysm stent grafts, abdominal aortic aneurysm stent grafts, Iliac artery bifurcation stent grafts, aortic stent graft
More news about: LifeTech Scientific Corporation
Mar 30, 2026, 08:49 ET Chinese Medical Association Publishing House Co., Ltd. Sheds Light on New Noninvasive Clues to Detect Portal Hypertension
hypertension (PH), a serious complication of liver cirrhosis, is defined as a pressure gradient > 5 mmHg between the portal vein and the inferior vena cava. When the hepatic venous pressure gradient (HVPG) exceeds 10 mmHg, the condition becomes clinically significant, and complications rise substantially,
More news about: Chinese Medical Association Publishing House Co., Ltd
Mar 19, 2026, 06:00 ET Canadian Solar Reports Fourth Quarter and Full Year 2025 Results
commercial operation in Q2 2027.On December 17, 2025, Canadian Solar announced that it would deliver 408 MWh AC Battery Energy Storage System to Vena Energy for its Tailem Bend 3 project in South Australia. The project is under construction and is targeted to begin operation in 2027. Under an initial
More news about: Canadian Solar Inc.
Mar 03, 2026, 17:46 ET Global Peripheral Vascular Devices Market Poised for Robust Growth at a CAGR of ~6% Through 2032 as Demand for Minimally Invasive Treatments Surges | DelveInsight
[Atherectomy Devices and Thrombectomy Devices], Hemodynamic Flow Alteration Devices [Embolic Protection Devices and Chronic Total Occlusion Devices], Inferior Vena cava Filters [Retrievable and Permanent], and OthersPeripheral Vascular Devices Market Segmentation By End User: Hospitals, Specialty
More news about: DelveInsight Business Research, LLP
Mar 03, 2026, 12:00 ET RELIEF CARDIOVASCULAR REPORTS POSITIVE FIRST-IN-HUMAN DATA FOR DEVICE-BASED DECONGESTION THERAPY IN HEART FAILURE PATIENTS
strategies, which are often constrained by renal impact."The Relief System is an integrated valve-and-sensor implant positioned in the inferior vena cava below the renal veins to directly modulate venous pressure and increase renal perfusion. The system collects daily venous pressure waveforms and
More news about: Relief Cardiovascular
Feb 13, 2026, 11:05 ET InVera Medical obtiene la aprobación de la marca CE europea para su nuevo dispositivo de infusión venosa
dispositivo utiliza un catéter delgado que se inserta en la vena bajo guía ecográfica, una técnica ya familiar para muchos médicos, y está diseñado para mejorar la infusión de agentes especificados por el médico de manera más efectiva dentro de la vena.La enfermedad venosa crónica afecta a aproximadamente
More news about: InVera Medical
Feb 06, 2026, 11:20 ET Field Medical presenta datos de última hora del ensayo Field PULSE en el Simposio de AF de 2026
reasignación demostró una mejora progresiva en la durabilidad de PVI con la forma de onda optimizadaPor vena: 94,2%Por paciente: 84,6%Resultados de seguridad:
More news about: Field Medical, Inc.
Feb 03, 2026, 13:44 ET Nucleus Research Releases 2026 CPM Technology Value Matrix
Leaders in the CPM market include Board, Infor EPM, Oracle EPM, Prophix, Vena Solutions, and Wolters Kluwer CCH Tagetik.MIAMI, Feb. 3, 2026 /PRNewswire/ -- Corporate performance management (CPM) in 2026
More news about: Nucleus Research
Feb 03, 2026, 08:00 ET El ensayo RESTART de Volta Medical muestra resultados prometedores para fibrilación auricular
pacientes más desafiantes en el cuidado de la fibrilación auricular, individuos con FA recurrente a pesar del aislamiento duradero confirmado de la vena pulmonar. 1,2 Estos pacientes históricamente han enfrentado bajas tasas de éxito con estrategias empíricas. 1,2 Al aprovechar
More news about: Volta Medical
Jan 16, 2026, 00:00 ET Zylox-Tonbridge to Acquire Equity Interest in A European Medical Device Company to Accelerate Expansion in the Global MedTech Market
product portfolios in the peripheral venous stenting market, including specialized devices for the iliofemoral veins, the iliac bifurcation and the vena cava. Optimed's dedicated venous stents are supported by high-evidence clinical trials such as the sinus-Venous, is supported by robust clinical evidence
More news about: ZYLOX-TONBRIDGE
Jan 15, 2026, 21:27 ET Zylox-Tonbridge to Acquire Equity Interest in A European Medical Device Company to Accelerate Expansion in the Global MedTech Market
product portfolios in the peripheral venous stenting market, including specialized devices for the iliofemoral veins, the iliac bifurcation and the vena cava. Optimed's dedicated venous stents are supported by high-evidence clinical trials such as the sinus-Venous, is supported by robust clinical evidence
More news about: ZYLOX-TONBRIDGE
Jan 06, 2026, 05:57 ET GORE GAINS FDA APPROVAL FOR FIRST DEEP VENOUS STENT INDICATED FOR THE IVC AND ILIOFEMORAL VEINS
FORTEGRA Venous Stent — previously known as the GORE® VIAFORT Vascular Stent — the first device for the treatment of deep venous disease in the inferior vena cava (IVC), iliac and iliofemoral veins.
More news about: W. L. Gore & Associates, Inc. MPD Division
Dec 17, 2025, 07:00 ET e-STORAGE to Deliver 408 MWh Battery Energy Storage System for Vena Energy in South Australia
South Australia and further support renewable energy integration, building on Vena Energy's previous developments in the region.Owen Sela, Head of Australia at Vena Energy, said, "The Tailem Bend 3 BESS will be Vena Energy's third energy storage project in Australia, underscoring our continued
More news about: Canadian Solar Inc.
Dec 12, 2025, 11:45 ET Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
vein thrombosis, pulmonary embolism, pelvic venous thrombosis, cerebral venous sinus thrombosis, subclavian and axillary vein thrombosis, and inferior vena cava thrombosis. In clinical trials, deaths due to VTE have been reported in patients treated with Verzenio.Verzenio has not been
More news about: Eli Lilly and Company